Articles

CPHI 2024 will return to the Fiera Milano in Milan, Italy.

CPHI to Return to Milan in 2024

Zygel is the first and only pharmaceutically manufactured, synthetic cannabidiol that is formulated as a patient-protected permeation-enhanced gel for transdermal delivery.

Harmony Biosciences to Acquire Zynerba Pharmaceuticals

The acquisition of the latter includes the company’s lead development asset INV-202, an oral CB1 inverse agonist which is designed to block the receptor protein CB1. 

Novo Nordisk to Acquire Inversago Pharma

Feliza Mirasol is the science editor for 

The completion of three acquisitions of Versanis Bio, Sigilon Therapeutics, and DICE Therapeutics boosts Eli Lilly and Company’s product pipeline in obesity, diabetes, and immunology.

Lilly Completes Spate of Acquisitions

Under the exclusive agreement, Hikma will commercialize products in Rakuten Medical’s pipeline for cancer treatment in the Middle East and North Africa region.

Rakuten Medical Signs Exclusive Licensing Agreement with Hikma for Cancer Treatments in MENA

A report from the UK Bioindustry Association report indicated that biotech venture and public financing rose from £295 million in the first quarter to £382 million in the second quarter.

United Kingdom Biotech Report Finds 29% Uptick in Funding

Cytomos will use the £4 million in funding to develop its dielectric spectroscopy technology.

Cytomos Secures £4 Million to Develop Spectroscopy Platform

Additionally, Poseida has approved Astellas as a board observer seat, which gives Astellas the right to attend Poseida’s scientific advisory board meetings and certain notice rights related to any potential change of control over Poseida.

Astellas and Poseida Therapeutics Plan to Invest in Redefining Cancer Cell Therapy 

Novartis has completed its acquisition of biopharma company Chinook Therapeutics.  

Novartis Finalizes Chinook Therapeutics Acquisition in Deal Worth Up to $3.5 Billion

The guidance can help both applicants and manufacturers limit the mutagenic and carcinogenic potential of NDSRIs.

News